Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Spotlight on Epigenetics in Hematologic Malignancies

The mechanistic role of DNA methylation in myeloid leukemogenesis

Leukemia volume 28, pages 1765–1773 (2014)Cite this article

Subjects

Abstract

The importance of epigenetic aberrations in the pathogenesis of leukemias has been revealed by recurrent gene mutations that highlight epigenetic pathways as well as by the clinical success of therapies like 5-azacytidine and decitabine that work through epigenetic mechanisms. However, precise mechanisms of how gene mutations lead to leukemias and how epigenetic therapies induce clinical remissions are elusive. Current scientific inquiries that take advantage of techniques that can distinguish among the various covalent cytosine modifications at single base resolution are likely to shed light on the ways epigenetic pathways drive leukemogenesis as well as how the hypomethylating drugs induce clinical remissions. The hope is that these studies will also reveal which patients are likely to respond to epigenetic therapies. Thus, the future is likely to bring a new wave of diagnostic and prognostic tools that probe the epigenomics of leukemia to help clinicians in their management of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P . Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 2013; 14: 765–780.

    CAS  Google Scholar 

  2. Helin K, Dhanak D . Chromatin proteins and modifications as drug targets. Nature 2013; 502: 480–488.

    Article  CAS  Google Scholar 

  3. Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR . Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010; 29: 576–588.

    CAS  Google Scholar 

  4. Neff T, Armstrong SA . Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood 2013; 121: 4847–4853.

    CAS  Google Scholar 

  5. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982; 10: 2709–2721.

    CAS  Google Scholar 

  6. Timp W, Feinberg AP . Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13: 497–510.

    CAS  Google Scholar 

  7. Feinberg AP, Vogelstein B . Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89–92.

    CAS  Google Scholar 

  8. Estecio MR, Issa JP . Dissecting DNA hypermethylation in cancer. FEBS Lett 2011; 585: 2078–2086.

    CAS  Google Scholar 

  9. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41: 178–186.

    CAS  Google Scholar 

  10. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 2008; 452: 215–219.

    CAS  Google Scholar 

  11. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315–322.

    CAS  Google Scholar 

  12. Bird A . DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6–21.

    CAS  Google Scholar 

  13. Wyatt MD . Advances in understanding the coupling of DNA base modifying enzymes to processes involving base excision repair. Adv Cancer Res 2013; 119: 63–106.

    CAS  Google Scholar 

  14. Teperek-Tkacz M, Pasque V, Gentsch G, Ferguson-Smith AC . Epigenetic reprogramming: is deamination key to active DNA demethylation? Reproduction 2011; 142: 621–632.

    CAS  Google Scholar 

  15. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860–921.

    CAS  Google Scholar 

  16. Franchini DM, Schmitz KM, Petersen-Mahrt SK . 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu Rev Genet 2012; 46: 419–441.

    CAS  Google Scholar 

  17. Branco MR, Ficz G, Reik W . Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet 2012; 13: 7–13.

    CAS  Google Scholar 

  18. Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep 2014; 6: 231–244.

    CAS  Google Scholar 

  19. Mariani CJ, Madzo J, Moen EL, Yesilkanal A, Godley LA . Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) 2013; 5: 786–814.

    CAS  Google Scholar 

  20. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667–11672.

    CAS  Google Scholar 

  21. Schmitz KM, Mayer C, Postepska A, Grummt I . Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. Genes Dev 2010; 24: 2264–2269.

    CAS  Google Scholar 

  22. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113: 6411–6418.

    CAS  Google Scholar 

  23. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473–7478.

    CAS  Google Scholar 

  24. Froberg JE, Yang L, Lee JT . Guided by RNAs: X-inactivation as a model for lncRNA function. J Mol Biol 2013; 425: 3698–3706.

    CAS  Google Scholar 

  25. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 2013; 152: 727–742.

    CAS  Google Scholar 

  26. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol 2013; 182: 64–70.

    CAS  Google Scholar 

  27. Lu L, Zhu G, Zhang C, Deng Q, Katsaros D, Mayne ST et al. Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer. Breast Cancer Res Treat 2012; 136: 875–883.

    CAS  Google Scholar 

  28. Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013; 210: 2641–2659.

    CAS  Google Scholar 

  29. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723–3731.

    CAS  Google Scholar 

  30. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.

    CAS  Google Scholar 

  31. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43: 309–315.

    CAS  Google Scholar 

  32. Kim SJ, Zhao H, Hardikar S, Singh AK, Goodell MA, Chen T . A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013; 122: 4086–4089.

    CAS  Google Scholar 

  33. Pawlak M, Jaenisch R . De novo DNA methylation by Dnmt3a and Dnmt3b is dispensable for nuclear reprogramming of somatic cells to a pluripotent state. Genes Dev 2011; 25: 1035–1040.

    CAS  Google Scholar 

  34. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE . The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116: 2779–2782.

    CAS  Google Scholar 

  35. Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118: 409–412.

    CAS  Google Scholar 

  36. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593–5603.

    CAS  Google Scholar 

  37. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373–1381.

    Google Scholar 

  38. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.

    Article  CAS  Google Scholar 

  39. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553–567.

    CAS  Google Scholar 

  40. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012; 44: 23–31.

    CAS  Google Scholar 

  41. Jeong M, Sun D, Luo M, Huang Y, Challen GA, Rodriguez B et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 2014; 46: 17–23.

    CAS  Google Scholar 

  42. Yu M, Hon GC, Szulwach KE, Song CX, Jin P, Ren B et al. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Nat Protoc 2012; 7: 2159–2170.

    CAS  Google Scholar 

  43. Yu M, Hon GC, Szulwach KE, Song CX, Zhang L, Kim A et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 2012; 149: 1368–1380.

    CAS  Google Scholar 

  44. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, Reik W et al. Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 2012; 336: 934–937.

    CAS  Google Scholar 

  45. Booth MJ, Ost TW, Beraldi D, Bell NM, Branco MR, Reik W et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat Protoc 2013; 8: 1841–1851.

    CAS  Google Scholar 

  46. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

    CAS  Google Scholar 

  47. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.

    CAS  Google Scholar 

  48. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.

    CAS  Google Scholar 

  49. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P et al. 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome—a systematic review and meta-analysis. Haematologica 2010; 95: 303–310.

    CAS  Google Scholar 

  50. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 1388–1394.

    CAS  Google Scholar 

  51. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004; 64: 4294–4301.

    CAS  Google Scholar 

  52. Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res 2013; 19: 938–948.

    CAS  Google Scholar 

  53. Jones PA, Taylor SM . Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85–93.

    CAS  Google Scholar 

  54. Li LH, Olin EJ, Buskirk HH, Reineke LM . Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970; 30: 2760–2769.

    CAS  Google Scholar 

  55. Flatau E, Gonzales FA, Michalowsky LA, Jones PA . DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol 1984; 4: 2098–2102.

    CAS  Google Scholar 

  56. Santi DV, Norment A, Garrett CE . Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984; 81: 6993–6997.

    CAS  Google Scholar 

  57. Datta J, Ghoshal K, Motiwala T, Jacob ST . Novel insights into the molecular mechanism of action of DNA hypomethylating agents: role of protein kinase C delta in decitabine-induced degradation of DNA methyltransferase 1. Genes Cancer 2012; 3: 71–81.

    Google Scholar 

  58. Taylor SM, Jones PA . Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979; 17: 771–779.

    CAS  Google Scholar 

  59. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495–5503.

    CAS  Google Scholar 

  60. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957–2964.

    CAS  Google Scholar 

  61. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F . Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008; 7: 2998–3005.

    CAS  Google Scholar 

  62. Stresemann C, Lyko F . Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. J Int Cancer 2008; 123: 8–13.

    CAS  Google Scholar 

  63. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009; 114: 2764–2773.

    CAS  Google Scholar 

  64. Claus R, Pfeifer D, Almstedt M, Zucknick M, Hackanson B, Plass C et al. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leukemia Res 2013; 37: 190–196.

    CAS  Google Scholar 

  65. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 2013; 121: 1633–1643.

    CAS  Google Scholar 

  66. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP . Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008; 111: 2382–2384.

    CAS  Google Scholar 

  67. Suzuki H, Maruyama R, Yamamoto E, Kai M . DNA methylation and microRNA dysregulation in cancer. Mol Oncol 2012; 6: 567–578.

    CAS  Google Scholar 

  68. Baer C, Claus R, Plass C . Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013; 73: 473–477.

    CAS  Google Scholar 

  69. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5: e9001.

    Google Scholar 

  70. Lu LW, Chiang GH, Medina D, Randerath K . Drug effects on nucleic acid modification. I. A specific effect of 5-azacytidine on mammalian transfer RNA methylation in vivo. Biochem Biophys Res Commun 1976; 68: 1094–1101.

    CAS  Google Scholar 

  71. Lu LJ, Randerath K . Effects of 5-azacytidine on transfer RNA methyltransferases. Cancer Res 1979; 39: 940–949.

    CAS  Google Scholar 

  72. Schaefer M, Hagemann S, Hanna K, Lyko F . Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 2009; 69: 8127–8132.

    CAS  Google Scholar 

  73. Xu J, Wang YY, Dai YJ, Zhang W, Zhang WN, Xiong SM et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci USA 2014; 111: 2620–2625.

    CAS  Google Scholar 

  74. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11–24.

    CAS  Google Scholar 

  75. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25–38.

    CAS  Google Scholar 

  76. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA 2011; 108: 14566–14571.

    CAS  Google Scholar 

  77. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509–4518.

    CAS  Google Scholar 

  78. Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012; 26: 2216–2223.

    CAS  Google Scholar 

  79. Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW et al. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell 2013; 24: 310–323.

    CAS  Google Scholar 

  80. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210: 2627–2639.

    CAS  Google Scholar 

  81. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656–659.

    CAS  Google Scholar 

  82. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877–2887.

    CAS  Google Scholar 

  83. Chen C, Liu Y, Lu C, Cross JR, JPt Morris, Shroff AS et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974–1985.

    CAS  Google Scholar 

  84. Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C et al. Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia 2014; e-pub ahead of print 14 January 2014; doi:10.1038/leu.2014.18.

    CAS  Google Scholar 

Download references

Author information

Author notes

  1. J Jasielec and V Saloura: These authors contributed equally to this work.

Authors and Affiliations

  1. Section of Medicine/Hematology/Oncology, The University of Chicago, Chicago, IL, USA

    J Jasielec, V Saloura & L A Godley

  2. The University of Chicago Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA

    L A Godley

Authors
  1. J Jasielec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Saloura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L A Godley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L A Godley.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jasielec, J., Saloura, V. & Godley, L. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia 28, 1765–1773 (2014). https://doi.org/10.1038/leu.2014.163

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.163

This article is cited by

Search

Advanced search

Quick links